Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
CERO 
CERo Therapeutics Holdings, Inc. Common Stock (CERO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/04/2025: CERO (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $30
1 Year Target Price $30
| 0 | Strong Buy |
| 1 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -34.99% | Avg. Invested days 60 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/04/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.75M USD | Price to earnings Ratio - | 1Y Target Price 30 |
Price to earnings Ratio - | 1Y Target Price 30 | ||
Volume (30-day avg) 2 | Beta 0.32 | 52 Weeks Range 0.05 - 360.00 | Updated Date 12/4/2025 |
52 Weeks Range 0.05 - 360.00 | Updated Date 12/4/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -5.56 |
Earnings Date
Report Date 2025-11-19 | When After Market | Estimate -4.35 | Actual -9.1 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -210.22% | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 9295637 | Price to Sales(TTM) - |
Enterprise Value 9295637 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding 21102671 | Shares Floating 21052658 |
Shares Outstanding 21102671 | Shares Floating 21052658 | ||
Percent Insiders 0.15 | Percent Institutions 1.04 |
Upturn AI SWOT
CERo Therapeutics Holdings, Inc. Common Stock
Company Overview
History and Background
CERo Therapeutics Holdings, Inc. is a clinical-stage biotechnology company focused on developing novel immunotherapies for cancer. Details on founding year and specific milestones need further research.
Core Business Areas
- Oncology Immunotherapy: Focuses on developing innovative therapies that harness the body's immune system to fight cancer.
Leadership and Structure
Details on CERo Therapeutics' leadership team and organizational structure need further research.
Top Products and Market Share
Key Offerings
- Cell Therapy Platform (Details Required): Specific details regarding CERo Therapeutics's cell therapy platform and its market share data require further research. Competitors would include other companies in the cell therapy space.
Market Dynamics
Industry Overview
The oncology immunotherapy market is rapidly growing, driven by advancements in research and increasing cancer prevalence.
Positioning
CERo Therapeutics aims to establish a strong position by developing novel therapies that address unmet needs in cancer treatment.
Total Addressable Market (TAM)
The TAM for cancer immunotherapies is significant, projected to reach billions of dollars. CERo Therapeutics aims to capture a portion of this market through successful drug development.
Upturn SWOT Analysis
Strengths
- Novel immunotherapy approach
- Potential for breakthrough therapies
- Experienced scientific team (Details Required)
Weaknesses
- Early stage clinical development
- Limited financial resources
- High regulatory hurdles
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion into new cancer indications
- Advancements in immunotherapy technologies
Threats
- Competition from established players
- Clinical trial failures
- Changes in regulatory landscape
Competitors and Market Share
Key Competitors
- BMY
- MRK
- PFE
- GILD
Competitive Landscape
CERo Therapeutics faces significant competition from established pharmaceutical companies with greater resources and more advanced product pipelines.
Growth Trajectory and Initiatives
Historical Growth: Historical growth data requires further research.
Future Projections: Future growth projections depend on clinical trial outcomes and regulatory approvals. Analyst estimates require further research.
Recent Initiatives: Recent strategic initiatives undertaken by CERo Therapeutics need further research.
Summary
CERo Therapeutics is an early-stage biotechnology company developing cancer immunotherapies. Its success depends on positive clinical trial outcomes and securing partnerships. The company faces significant competition and regulatory hurdles, and needs to carefully manage its limited financial resources to achieve long-term growth.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Publicly available information
- Company press releases (if available)
- Industry reports (if available)
Disclaimers:
This analysis is based on limited information and may not be entirely accurate. Investment decisions should be based on thorough research and consultation with a financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About CERo Therapeutics Holdings, Inc. Common Stock
Exchange NASDAQ | Headquaters South San Francisco, CA, United States | ||
IPO Launch date 2024-02-15 | CEO & Chair Mr. Christopher B. Ehrlich M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 8 | Website https://www.cero.bio |
Full time employees 8 | Website https://www.cero.bio | ||
CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead development candidate is CER-1236, an autologous T cell therapy candidate for the treatment of hematologic malignancies and solid tumors. The company was incorporated in 2021 and is based in South San Francisco, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.